CCCC Deferred Long Term Liab from 2010 to 2025
| CCCC Stock | USD 1.75 0.09 4.89% |
Deferred Long Term Liabilities | First Reported 2010-12-31 | Previous Quarter 21.9 M | Current Value 31.2 M | Quarterly Volatility 13.7 M |
Check C4 Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among C4 Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 230.2 K, Net Interest Income of 15.2 M or Interest Income of 15.2 M, as well as many indicators such as Price To Sales Ratio of 30.95, Dividend Yield of 0.0 or PTB Ratio of 1.08. CCCC financial statements analysis is a perfect complement when working with C4 Therapeutics Valuation or Volatility modules.
CCCC | Deferred Long Term Liab |
Latest C4 Therapeutics' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of C4 Therapeutics over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. C4 Therapeutics' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in C4 Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
CCCC Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 44,751,012 | |
| Geometric Mean | 42,278,546 | |
| Coefficient Of Variation | 30.62 | |
| Mean Deviation | 12,190,733 | |
| Median | 53,617,000 | |
| Standard Deviation | 13,700,611 | |
| Sample Variance | 187.7T | |
| Range | 31.7M | |
| R-Value | (0.79) | |
| Mean Square Error | 76.9T | |
| R-Squared | 0.62 | |
| Significance | 0.0003 | |
| Slope | (2,261,740) | |
| Total Sum of Squares | 2815.6T |
CCCC Deferred Long Term Liab History
About C4 Therapeutics Financial Statements
C4 Therapeutics stakeholders use historical fundamental indicators, such as C4 Therapeutics' Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although C4 Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in C4 Therapeutics' assets and liabilities are reflected in the revenues and expenses on C4 Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in C4 Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 21.9 M | 31.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of C4 Therapeutics Correlation against competitors. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share | Quarterly Revenue Growth 0.588 | Return On Assets | Return On Equity |
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.